Literature DB >> 32067923

Traditional Chinese medicine targeting cancer stem cells as an alternative treatment for hepatocellular carcinoma.

Kai-Yue Tang1, Shi-Lin Du2, Qian-Lei Wang1, Yi-Fan Zhang1, Hai-Yan Song3.   

Abstract

Hepatocellular carcinoma (HCC) is a prevalent and highly malignant cancer throughout the world. Effective treatment of this disease is impeded by the high rate of metastasis, recurrence, and chemoresistance. Recent studies have revealed the close relationship between the malignant phenotype of HCC and cancer stem cells (CSCs). Therefore, CSC-targeted therapy is considered a promising strategy to eradicate HCC. Traditional Chinese medicine (TCM) can be effective in preventing recurrence and metastasis of some advanced HCC. A growing amount of literature has discovered that extracts or compounds derived from TCM exert an anti-CSC effect. This review introduces some formulas and chemical compounds derived from TCMs that have been reported to inhibit CSCs of HCC; these TCM-related drugs may help to provide an alternative approach to help manage cancers, especially for HCC which has a great potential of metastasis, recurrence, and chemoresistance.
Copyright © 2020 Shanghai Changhai Hospital. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer stem cells; Hepatocellular carcinoma; Traditional Chinese medicine

Year:  2020        PMID: 32067923     DOI: 10.1016/j.joim.2020.02.002

Source DB:  PubMed          Journal:  J Integr Med


  9 in total

1.  Site-Directed Mutagenesis Improves the Transduction Efficiency of Capsid Library-Derived Recombinant AAV Vectors.

Authors:  Gai Ran; Xiao Chen; Yilin Xie; Qingyun Zheng; Jinyan Xie; Chenghui Yu; Nikea Pittman; Sixian Qi; Fa-Xing Yu; Mavis Agbandje-McKenna; Arun Srivastava; Chen Ling
Journal:  Mol Ther Methods Clin Dev       Date:  2020-03-13       Impact factor: 6.698

Review 2.  Using Traditional Chinese Medicine to Treat Hepatocellular Carcinoma by Targeting Tumor Immunity.

Authors:  Wentao Jia; Lina Wang
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-11       Impact factor: 2.629

3.  Network Pharmacology-Oriented Identification of Key Proteins and Signaling Pathways Targeted by Xihuang Pill in the Treatment of Breast Cancer.

Authors:  Jiafa Wu; Dongping Luo; Shengnan Li
Journal:  Breast Cancer (Dove Med Press)       Date:  2020-12-08

4.  Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?

Authors:  Yuqian Feng; Huimin Jin; Kaibo Guo; Yuying Xiang; Yiting Zhang; Wurong Du; Minhe Shen; Shanming Ruan
Journal:  Front Pharmacol       Date:  2021-02-25       Impact factor: 5.810

5.  Biejiajian Pill Promotes the Infiltration of CD8+ T Cells in Hepatocellular Carcinoma by Regulating the Expression of CCL5.

Authors:  Xuemei Yang; Jialing Sun; Bin Wen; Yu Wang; Mingjia Zhang; Weicong Chen; Wenting Zhao; Chunyu He; Xiaodan Zhong; Yang Liu; Tong Li; Haitao Sun; Songqi He
Journal:  Front Pharmacol       Date:  2021-11-26       Impact factor: 5.810

6.  Overexpression of miR-651-5p inhibits ultraviolet radiation-induced malignant biological behaviors of sebaceous gland carcinoma cells by targeting ZEB2.

Authors:  Haiyan Zhao; Xiaochun Yang; Juan Liu; Fang Han; Zhengrong Yang; Zhongyin Hu; Mingzhi Liu; Yan Mei
Journal:  Ann Transl Med       Date:  2022-05

Review 7.  Frontier progress of the combination of modern medicine and traditional Chinese medicine in the treatment of hepatocellular carcinoma.

Authors:  Lai Wei; Zeyu Wang; Niancai Jing; Yi Lu; Jili Yang; Hongyu Xiao; Huanyu Guo; Shoukun Sun; Mingjing Li; Daqing Zhao; Xiangyan Li; Wenxiu Qi; Yue Zhang
Journal:  Chin Med       Date:  2022-07-30       Impact factor: 4.546

8.  Genetic Toxicology and Safety Pharmacological Evaluation of Forsythin.

Authors:  Zhong Han; Jianmin Guo; Feibiao Meng; Haifeng Liao; Yinghua Deng; Yuankeng Huang; Xialing Lei; Chun Liang; Richou Han; Wei Yang
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-18       Impact factor: 2.629

9.  Knockdown of circ_0001883 may inhibit epithelial-mesenchymal transition in laryngeal squamous cell carcinoma via the miR-125-5p/PI3K/AKT axis.

Authors:  Fu Chen; Zheng Lao; Haiyan Zhang; Jie Wang; Shengzi Wang
Journal:  Exp Ther Med       Date:  2021-07-15       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.